Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Refractory Lupus
NCT02633163Phase 2Completed
- Sponsor
- Medical University of South Carolina
- Start
- Nov 2018
- Primary completion
- Aug 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in systemic lupus erythematosus (SLE) (3 arms), sponsored by Medical University of South Carolina. Primary endpoint: SLE Responder Index at 24 weeks. Started Nov 2018; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02633163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633163.